The Cooper Companies carries a Zacks Rank #3 (Hold) and a Neutral recommendation as premium contact lens momentum from MyDay is weighed down by Asia-Pacific weakness, litigation costs, and leverage. MyDay delivered double-digit growth in the second quarter of fiscal 2026, and CooperSurgical fertility revenues rose 10% organically to $143.8 million, but CooperVision’s Asia-Pacific sales fell 6% organically to $130.6 million, with further declines expected in the third quarter. The company recorded a $271.6 million net pre-tax charge tied to a fertility media recall, though it raised its fiscal 2026 free cash flow outlook to roughly $650 million excluding litigation payouts. Cash and equivalents stood at $138.8 million against total debt of $2.46 billion as of April 2026, keeping debt reduction in focus. The stock has a VGM Score of B with Value and Growth Scores of B, but a Momentum Score of D points to limited near-term price or estimate momentum.
The Cooper Companies, IncAsia-Pacific sales fell 6% organically with further declines expected
Alcon AG
Bausch + Lomb Corp